| Treprostinil is approved for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. |
| The antifibrotic effects of treprostinil are mediated through the activation of the prostaglandin E receptor 2, the prostaglandin D receptor 1, and peroxisome proliferator-activated receptors. |
| Preclinical and clinical data provide evidence for the antifibrotic effects of treprostinil. |
| Treprostinil may have a role in mitigating the effects of fibrosis caused by vascular remodeling, cytokine overexpression, and alveolar wall thickening. |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.